SYSNAV Healthcare announces that the European Medicines Agency considers that for ambulant Duchenne Muscular Dystrophy patients four years of age and above, Stride Velocity 95th centile qualifies as primary endpoint in superiority studies as an alternative to the 6 Minute Walking Test provided this outcome measure is supported by consistent findings in established efficacy endpoints included in secondary endpoints.
